 |
|
Which is promising as therapeutic targets in patients with biliary tract cancer? EGFR or HER2?
October 16, 2009The epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2) are involved in the carcinogenesis of many malignancies. Therapeutic molecules targeting EGFR and HER2 have been successfully used for the treatment of colorectal, breast, lung and head and neck cancers among others. It is unknown if EGFR and HER2 are overexpressed in advanced biliary tract cancer (BTC) and therefore may serve as therapeutic targets in these cancers.
A research article to be published on September 28, 2009 in the World Journal of Gastroenterology addresses this question. A research team from Germany studied EGFR and HER2 expression in biopsy samples from 124 patients (51% women; median age 64.8 years), with advanced BTC diagnosed between 1997 and 2004. Five micrometers sections of paraffin embedded tissue were examined by standard, FDA approved immunohistochemistry. Tumors with scores of 2+ or 3+ for HER2 expression on immunochemistry were additionally tested for HER2 gene amplification by fluorescence in situ hybridisation (FISH). The results showed 34/124 patients (27.4%) had gallbladder cancer, 47 (37.9%) had intrahepatic BTC and 43 (34.7%) had extrahepatic or perihilar BTC. EGFR expression was examined in a subset of 56 samples. EGFR expression was absent in 22/56 tumors (39.3%). Of the remaining samples expression was scored as 1+ in 12 (21.5%), 2+ in 13 (23.2%) and 3+ in 9 (16%), respectively. HER2 expression was as follows: score 0 73/124 (58.8%), score 1+ 27/124 (21.8%), score 2+ 21/124 (17%) and score 3+ 4/124 (3.2%). HER2 gene amplification was present in 6/124, resulting in an overall amplification rate of 5%.
Their findings demonstrate that EGFR overexpression is frequent in BTC. In contrast, HER2 overexpression and gene amplification is a rare event. They concluded that routine testing and therapeutic targeting of HER2 does not seem to be useful in patients with BTC, while targeting EGFR may be promising.
World Journal of Gastroenterology
World Journal of Gastroenterology
Epidermal Growth Current Events and Epidermal Growth News RSSEarly-stage, HER2-positive breast cancer patients at increased risk of recurrence
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who do not express the aggressive protein, according to a study led by researchers at The University of Texas M. D. Anderson Cancer Center.
Alcohol activates cellular changes that make tumor cells spread
Alcohol consumption has long been linked to cancer and its spread, but the underlying mechanism has never been clear.
African American lung cancer patients may have different response to new cancer-fighting drugs
Clinical research out of University Hospitals Case Medical Center has found that African Americans with a common form of lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to new cancer-fighting drugs.
Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent
Patients with advanced non-small cell lung cancer who are given cetuximab (Erbitux) in addition to chemotherapy are 13% less likely to die than those who receive chemotherapy alone, regardless of which chemotherapy drug cocktail is used, new research finds. They also experience slower disease progression and an increased chance of tumour shrinkage.
Prodrug could help curb skin toxicity related to EGFR-inhibiting cancer drugs
There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.
Fox Chase finds that lung cancer patients respond to erlotinib following cetuximab therapy
Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported today at the annual meeting of the International Association for the Study of Lung Cancer.
Protein That Promotes Cancer Cell Growth Identified
Scientists at Burnham Institute for Medical Research (Burnham) have found that the Caspase-8 protein, long known to play a major role in promoting programmed cell death (apoptosis), helps relay signals that can cause cancer cells to proliferate, migrate and invade surrounding tissues.
Stealthy gene network makes brain tumors flourish
The brain tumor afflicting Sen. Edward Kennedy - a glioblastoma - is the most aggressive and wily form of brain cancer.
Newly appreciated membrane estrogen receptor important therapeutic target for breast cancer
New research at Rhode Island Hospital has uncovered the biological effects of a novel membrane estrogen receptor, a finding that has potential implications for hormonal therapy for breast cancer.
Neural stem cell differentiation factor discovered
Neural stem cells represent the cellular backup of our brain. These cells are capable of self-renewal to form new stem cells or differentiate into neurons, astrocytes or oligodendrocytes.
More Epidermal Growth Current Events and Epidermal Growth News Articles
|
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.(CASE REPORTS): An article from: Journal of Drugs in Dermatology by Elizabeth V. Seiverling (Author), Emmy M. Fernanadez (Author), David Adams (Author) This digital document is an article from Journal of Drugs in Dermatology, published by Thomson Gale on April 1, 2006. The length of the article is 963 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.(CASE REPORTS) Author: Elizabeth V. Seiverling Publication: Journal of Drugs in Dermatology (Magazine/Journal) Date: April 1, 2006 Publisher: Thomson Gale Volume: 5 Issue: 4 Page: 368(2) Distributed by Thomson... | |
 |
Arcona Hydrating Serum 30ml by Arcona, Inc. Skin hydrator rescues dehydrated and depleted skin by replenishing lipids lost in aging, stress and environmental damage. Attract and bind moisture to skin with hyaluronic acid, a powerful natural hydrator. Nourish and protect skin with healing Manuka honey, rich in vitamins, minerals and amino acids that assist cellular regeneration. Lock in moisture to maximize the benefits of a daily hydrating regimen, for a healthier, more youthful complexion. Made in USA Please recycle |
|
A Network Model of a Cooperative Genetic Landscape / Monosomy of Chromosome 10 Associated With Dysregulation of Epidermal Growth Factor Signaling in Gliblastomas / Hormaone Therapy and Ovarian Cancer (JAMA: The Journal of the American Medical Association, Volume 302, Number 3, July 15) by D.M. M. Bredel (Author) | |
|
Biochemical and Biophysical Research Communications. Volume 176. Pp. 1-774. 1991. 1.25-Dihydroxyvitamin D, Increases Epidermal Growth Factor Receptor Gene Expression in BT-20 Breast Carcinoma Cells by Desprez et al. etc. by Desprez et al (Author) | |
 |
Epidermal Growth Factors and Cytokines (Basic and Clinical Dermatology) by T. A. Luger (Author) This reference enhances the understanding of skin pathophysiology by examining a selection of cytokines and growth factors that are either produced by the skin or have an influence on it.;Illustrating the importance of cytokine and growth factor interactions within the cytokine network, Epidermal Growth Factors and Cytokines: discusses a variety of cytokines, including the interferons, tumor necrosis factor, and interleukins 1, 6, 8, and 10; describes platelet-derived growth factor, fibroblast growth factors, and transforming growth factor -alpha and -beta; elucidates the skin's cytokine network, covering topics such as cytokines and wound healing, langerhans cells, mast cells, and endothelial cells; and explores cytokine therapies for skin disease.;With over 2800 literature citations,... |
|
FDA approves Erbitux for metastatic colorectal ca; first targeted treatment for such disease.(Binds to Epidermal Growth Factor Receptor): An article from: Internal Medicine News by Elizabeth Mechcatie (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on March 15, 2004. The length of the article is 928 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: FDA approves Erbitux for metastatic colorectal ca; first targeted treatment for such disease.(Binds to Epidermal Growth Factor Receptor) Author: Elizabeth Mechcatie Publication: Internal Medicine News (Magazine/Journal) Date: March 15, 2004 Publisher: International Medical News Group Volume: 37 Issue: 6 Page: 1(2) Distributed by Thomson... | |
|
Abgenix and Amgen clarify responsibilities for epidermal growth factor receptor antibody agreement.: An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on October 1, 2003. The length of the article is 449 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Abgenix and Amgen clarify responsibilities for epidermal growth factor receptor antibody agreement. Publication: BIOTECH Patent News (Newsletter) Date: October 1, 2003 Publisher: Biotech Patent News Volume: 17 Issue: 10 Distributed by Thomson... | |
 |
Cancer Over-expressed Receptors as Targets for PET Molecular Imaging: Androgen and Epidermal Growth Factor (EGF) Receptors as Targets for Molecular Imaging ... Using Positron Emission Tomography (PET) by Orit Jacobson (Author) Positron Emission Tomography (PET) is a nuclear medicine imaging technology which allows for four-dimensional, quantitative determination of the distribution of labeled biological compounds within the human body. The high sensitivity of PET and the low concentration of the tracers used, allow quantitative visualization of low capacity biochemical systems such as receptors. Epidermal growth factor receptor (EGFR) is involved in proliferation, cell movement, cell survival and differentiation of both normal and malignant cells. EGFR over-expression has been detected in a variety of malignant epithelial tumors. Androgen Receptor (AR) plays a critical role in initiation and growth of prostate cancer cells. Nearly 80-90% of prostate cancers are dependent on androgen at... |
|
FDA approves novel assay for determining HER2 status.(News)(human epidermal growth factor receptor 2)(United States. Food and Drug Administration): An article from: Internal Medicine News by Alicia Ault (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on September 1, 2008. The length of the article is 380 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser. Citation Details Title: FDA approves novel assay for determining HER2 status.(News)(human epidermal growth factor receptor 2)(United States. Food and Drug Administration) Author: Alicia Ault Publication: Internal Medicine News (Magazine/Journal) Date: September 1, 2008 Publisher: International Medical News Group Volume: 41 Issue: 17 Page: 8(1) Distributed by Gale, a part of Cengage... | |
 |
Epidermal Growth Factor: Webster's Timeline History, 2005 - 2007 by Icon Group International (Author) Webster's bibliographic and event-based timelines are comprehensive in scope, covering virtually all topics, geographic locations and people. They do so from a linguistic point of view, and in the case of this book, the focus is on "Epidermal Growth Factor," including when used in literature (e.g. all authors that might have Epidermal Growth Factor in their name). As such, this book represents the largest compilation of timeline events associated with Epidermal Growth Factor when it is used in proper noun form. Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including... |
| © 2009 BrightSurf.com |